Business
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of
About this update from Longeveron Inc.
[{"type":"text","content":"Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval and commercialization, mergers and acquisitions, and business development MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer. Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023. Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer. Hashad has vast experience leading drug development from Phase 1 to U.S. Food and Drug Administration (FDA) approval, working for both Fortune 500 pharmaceutical companies and early stage biotechnology companies. He has overseen mergers and acquisitions, business development deals, and drug commercialization for Amgen, Boehringer Ingelheim, Eli Lilly, and most recently Avanir, where he oversaw Avanir’s full integration into Otsuka’s United States operations. “The Board and I are delighted to welcome Mr. Hashad to Longeveron to lead the company through its next stage of growth. Mr. Hashad is an exceptional industry leader with deep operational and strategic expertise reaching across therapeutic areas,” said Longeveron co-founder and Chairman of the Board Joshua M. Hare, M.D. “His leadership and commitment to developing new therapeutic strategies will be invaluable to Longeveron as we continue to execute on key milestones across our three clinical programs, including our Phase 2 trials for Alzheimer’s Disease, Aging-Related Frailty, and hypoplastic left heart syndrome, a rare pediatric disease in neonates.” “I am honored to join Longeveron as CEO,” said Mr. Hashad. “With its robust clinical pipeline, Longeveron is well-positioned as a leader in regenerative medicines. I look forward to working with the Board, management, and the broader Longeveron team to continue the impressive progress to-date and advance Lomecel-BTM as a potential therapy across multiple disease are...